Monitor upcoming clinical data readouts for OCU400 (Q1 2027) and OCU410 (March 2026), which could be catalysts. The extended cash runway into Q4 2026 reduces near-term dilution risk, but investors should watch for potential warrant exercises from the Janus Henderson financing that could extend funding into Q2 2027.
Price Chart
Executive Summary
Ocugen reported financial results for Q4 and full year 2025, showing increased R&D spending and net losses, but highlighted significant clinical progress including completed enrollment in its OCU400 Phase 3 trial and positive preliminary data for OCU410. The company secured $22.5 million in financing to extend its cash runway into Q4 2026.
Key Financial Metrics
Key Facts
- Completed enrollment in OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa; topline data expected Q1 2027
- Positive preliminary Phase 2 data for OCU410 in geographic atrophy showed 46% lesion growth reduction
- Secured $22.5 million in gross proceeds through a registered direct offering in January 2026
- Cash and restricted cash totaled $18.9 million as of December 31, 2025, down from $58.8 million a year earlier
- Reported net loss of $0.06 per share in Q4 2025, compared to $0.05 per share in Q4 2024
Financial Impact
Net loss increased to $17.7 million in Q4 2025 from $13.9 million in Q4 2024, with cash declining by $39.9 million year-over-year
Risk Factors
- Cash position decreased significantly from $58.8 million to $18.9 million year-over-year, despite recent financing
- Net losses increased year-over-year, with R&D expenses rising from $32.1 million in 2024 to $39.8 million in 2025
- Future funding remains dependent on warrant exercises and potential partnerships
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-023288 |
| Document: tm267731d1_ex99-2.htm | 0001104659-26-023288 |
| Document: tm267731d1_8k.htm | 0001104659-26-023288 |
| Document: 0001104659-26-023288-index-headers.html | 0001104659-26-023288 |
| Document: 0001104659-26-023288-index.html | 0001104659-26-023288 |
| Document: 0001104659-26-023288.txt | 0001104659-26-023288 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | Press Release | $1.33 $1.05 | ▼ −21.05% | ▼ −22.23% | $1.02 (−22.93%) |
Jul 13, 2026 11w ago | 8-K | $1.41 $1.31 | ▼ −7.09% | ▼ −10.28% | $1.02 (−27.30%) |
Jun 11, 2026 16w ago | 8-K | $1.21 $1.47 | ▲ +21.49% | ▲ +19.71% | $1.02 (−15.29%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.22 $1.47 | ▲ +20.49% | ▲ +18.60% | $1.02 (−15.98%) |
May 5, 2026 21w ago | 8-K | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.21%) |
May 5, 2026 21w ago | Press Release | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.21%) |
May 5, 2026 21w ago | Press Release | $1.49 $1.34 | ▲ +10.07% | ▲ +15.02% | $1.02 (+31.21%) |
May 4, 2026 21w ago | 8-K | $1.49 $1.34 | ▼ −10.07% | ▼ −15.02% | $1.02 (−31.21%) |
Apr 29, 2026 22w ago | Press Release | $1.68 $1.38 | ▼ −17.86% | ▼ −23.32% | $1.02 (−38.99%) |
Mar 24, 2026 27w ago | Press Release | $1.92 $1.68 | ▼ −12.50% | ▼ −21.40% | $1.02 (−46.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access